Nifoxipam produces strong tranquillising and sleep-prolonging effects and has much lower toxicity compared to
lormetazepam and flunitrazepam in mice.[1]
^
abEP 0158267, Posselt K, Wagener HH, Gruber K,, "Pharmaceutical composition containing 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro- or 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one and process for their preparation", published 16 October 1985, assigned to Dolorgiet Beteiligungs-GmbH
^"Nifoxipam". New Synthetic Drugs Database. Archived from
the original on 2016-11-01. Retrieved 2016-07-08.
^Meyer MR, Bergstrand MP, Helander A, Beck O (May 2016). "Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes". Analytical and Bioanalytical Chemistry. 408 (13): 3571–91.
doi:
10.1007/s00216-016-9439-6.
PMID27071765.
S2CID25831532.
^Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. 9 (4): 640–645.
doi:
10.1002/dta.2003.
PMID27366870.
Nifoxipam produces strong tranquillising and sleep-prolonging effects and has much lower toxicity compared to
lormetazepam and flunitrazepam in mice.[1]
^
abEP 0158267, Posselt K, Wagener HH, Gruber K,, "Pharmaceutical composition containing 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro- or 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one and process for their preparation", published 16 October 1985, assigned to Dolorgiet Beteiligungs-GmbH
^"Nifoxipam". New Synthetic Drugs Database. Archived from
the original on 2016-11-01. Retrieved 2016-07-08.
^Meyer MR, Bergstrand MP, Helander A, Beck O (May 2016). "Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes". Analytical and Bioanalytical Chemistry. 408 (13): 3571–91.
doi:
10.1007/s00216-016-9439-6.
PMID27071765.
S2CID25831532.
^Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. 9 (4): 640–645.
doi:
10.1002/dta.2003.
PMID27366870.